Insilico Medicine vs Recursion Pharmaceuticals
Relationship
Both platforms screen and design drug candidates with AI/ML; Insilico's own HKEX prospectus names Recursion in its Competitive Landscape table.
1 of 8 capabilities — Shares drug discovery.
Ludbee capability tags · from the product recordsShared product type — Both ship platform.
Ludbee product recordsSame scale band — Both small-cap.
Ludbee scale bands · from valuation and funding figuresNamed in filing — “The table below shows the comparison of the major global AI pharmaceutical companies.”
www1.hkexnews.hk · checked 2025-12-18Find drug candidates faster — Rivals on this job — Screen, design or predict molecules and biological structure to shorten early-stage drug discovery, not run a clinical trial.
Ludbee needs vocabulary · the scope on the sourced edgeAligned comparison
Capability overlap
Shared · 1
Not verified for Recursion Pharmaceuticals · 7
Recorded for Insilico Medicine. Recursion Pharmaceuticals’s product records say nothing either way — a missing record is not a missing capability.
Recursion Pharmaceuticals has no capability Insilico Medicine lacks, among the 1 recorded here.
Products, side by side
Hand-checked pairing
Insilico Medicine
Platform
AI platform for de novo design and multi-property optimization of peptides, nanobodies and antibodies against specified targets and epitopes.
Generative small-molecule design platform combining de novo generation with physics-based methods, retrosynthesis, ADMET profiling and custom model training.
Foundation-model training and benchmarking platform that fine-tunes a customer's own LLM on Insilico's proprietary pharma reasoning datasets and validates results in its automation lab.
AI platform for therapeutic target identification, biomarker discovery, indication prioritization and drug repurposing over a multi-omics knowledge base.
End-to-end generative-AI platform spanning target discovery, molecular design and clinical-trial risk assessment for pharmaceutical research.
Recursion Pharmaceuticals
Platform
Drug-discovery platform combining automated cell-biology experiments with machine-learning models over the resulting data.
No counterpart
Insilico Medicine sells these in a stack layer with no product recorded for Recursion Pharmaceuticals yet — nothing on the other side to compare them against.
Application
AI research writing assistant that drafts structured, cited papers, reviews, grant proposals and abstracts against biomedical databases such as PubMed and bioRxiv.
Multimodal AI platform that forecasts the probability of success of individual clinical trials and scores alternative trial designs before implementation.
Hardware
On-premise AI appliance running PandaOmics target and biomarker discovery locally with no external data transmission, sold in Server and Desktop editions.